Help
Posted Wed, Apr, 23,2014
Published today in Clinical Medicine Insights: Therapeutics is a new review article by Taylor Y. Lu and Edward N. Rampersaud. Read more about this paper below:
Title
Pazopanib—the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma
Abstract
Kidney cancer is the most lethal of the genitourinary malignancies. Prior to the advent of cytokine-based immunotherapy 25 years ago, surgery was the only viable treatment for advanced renal cell carcinoma (RCC). Adjuvant therapy with interferon and interleukin-2 revolutionized the treatment paradigm, although responders were too often uncommon. The mid-portion of the last decade saw born a new class of drugs aimed at the angiogenesis/VEGF pathway, common to most clear-cell RCC. The latest FDA-approved compound in this class has promised to yield equal or better first-line efficacy as its predecessors while, perhaps, providing better tolerability. Here we review the available data at present regarding pazopanib.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesPublishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
Facebook Google+ Twitter
Pinterest Tumblr YouTube